AstraZeneca said its Crestor anti-cholesterol medicine failed to beat Pfizer's (PFE) Lipitor in a head-to-head clinical trial, dubbed Saturn. AstraZeneca had hoped the trial would differentiate Crestor and eat into Lipitor's $12 billion in sales.
While the Saturn trial showed Crestor had a "numerically greater" reduction in artery-clogging plaque in patients compared to Lipitor, the results were not statistically significant.
A secondary measure did show Crestor had a statistical significance over Lipitor, AstraZeneca said.AstraZeneca shares trading in London were down nearly 3%. -- Written by Robert Holmes in Boston.
>To contact the writer of this article, click here: Robert Holmes. >To follow Robert Holmes on Twitter, go to http://twitter.com/RobTheStreet. >To submit a news tip, send an email to: email@example.com.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV